modif cell nitestinale ap chir baria 2017 pharma.pdf


Aperçu du fichier PDF modif-cell-nitestinale-ap-chir-baria-2017-pharma.pdf

Page 1 2 3 4 5 6




Aperçu texte


34 Endocrine and metabolic diseases

endotoxemia initiates obesity and insulin resistance. Diabetes
2007, 56:1761-1772.
39. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y,
Parameswaran P, Crowell MD, Wing R, Rittmann BE et al.: Human
gut microbiota in obesity and after gastric bypass. Proc Natl
Acad Sci U S A 2009, 106:2365-2370.
40. Vrieze A, Van Nood E, Holleman F, Saloja¨rvi J, Kootte RS,
Bartelsman JFWM, Dallinga-Thie GM, Ackermans MT, Serlie MJ,
Oozeer R et al.: Transfer of intestinal microbiota from lean
donors increases insulin sensitivity in individuals with
metabolic syndrome. Gastroenterology 2012, 143 913–916.e7.
41. Furet J-P, Kong L-C, Tap J, Poitou C, Basdevant A, Bouillot J-L,
Mariat D, Corthier G, Dore´ J, Henegar C et al.: Differential
adaptation of human gut microbiota to bariatric surgeryinduced weight loss links with metabolic and low-grade
inflammation markers. Diabetes 2010, 59:3049-3057.
42. Liou AP, Paziuk M, Luevano J-M, Machineni S, Turnbaugh PJ,
Kaplan LM: Conserved shifts in the gut microbiota due to
gastric bypass reduce host weight and adiposity. Sci Transl
Med 2013, 5:178ra41.
43. Tremaroli V, Karlsson F, Werling M, Sta˚hlman M, Kovatcheva
Datchary P, Olbers T, Fa¨ndriks L, le Roux CW, Nielsen J,
Ba¨ckhed F: Roux-en-Y gastric bypass and vertical banded
gastroplasty induce long-term changes on the human gut
microbiome contributing to fat mass regulation. Cell Metab
2015, 22:228-238.
In this paper, the authors showed that Roux-en-Y gastric bypass and
vertical sleeve gastrectomy produce in humans long-term alterations of
the gut microbiome independently of BMI. By colonizing germ-free mice
with stools from the patients, they demonstrated that the surgically
altered microbiota promoted reduced fat deposition in recipient mice
adding evidence for the transmission ability of the human adiposity
phenotype through the gut microbiota.
44. Savassi-Rocha AL, Diniz MTC, Vilela EG, Diniz M de FHS,
Sanches SR, da Cunha AS, Ferrari M de L, Torres HO,
Maciente BA, Ataliba GS et al.: Changes in intestinal
permeability after Roux-en-Y gastric bypass. Obes Surg 2014,
24:184-190.
45. Casselbrant A, Elias E, Fa¨ndriks L, Wallenius V: Expression of
tight-junction proteins in human proximal small intestinal
mucosa before and after Roux-en-Y gastric bypass surgery.
Surg Obes Relat Dis 2015, 11:45-53.
46. Clemente-Postigo M, Roca-Rodriguez M del M, Camargo A,
Ocan˜a-Wilhelmi L, Cardona F, Tinahones FJ: Lipopolysaccharide
and lipopolysaccharide-binding protein levels and their
relationship to early metabolic improvement after bariatric
surgery. Surg Obes Relat Dis 2015, 11:933-939.

Current Opinion in Pharmacology 2017, 37:29–34

47. Blanchard C, Moreau F, Chevalier J, Ayer A, Garcon D, Arnaud L,
Pais de Barros J-P, Gautier T, Neunlist M, Cariou B et al.: Sleeve
gastrectomy alters intestinal permeability in diet-induced
obese mice. Obes Surg 2017 http://dx.doi.org/10.1007/s11695017-2670-1.
48. Gupta S, Allen-Vercoe E, Petrof EO: Fecal microbiota
transplantation: in perspective. Ther Adv Gastroenterol 2016,
9:229-239.
49. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB,
Guiot Y, Derrien M, Muccioli GG, Delzenne NM et al.: Cross-talk
between Akkermansia muciniphila and intestinal epithelium
controls diet-induced obesity. Proc Natl Acad Sci U S A 2013,
110:9066-9071.
50. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L,
Chilloux J, Ottman N, Duparc T, Lichtenstein L et al.: A purified
membrane protein from Akkermansia muciniphila or the
pasteurized bacterium improves metabolism in obese and
diabetic mice. Nat Med 2017, 23:107-113.
This paper demonstrate that a specific protein isolated from the outer
membrane of A. muciniphila named Amuc_1100 can improve the gut
barrier through its interaction with Toll-like receptor 2 and recapitulates
some beneficial effects of the bacterium. These findings provide support
for the use of A. muciniphila compounds as therapeutic options to target
human obesity and associated disorders.
51. Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzabal A, Lacy A,
Vidal J: Comparable early changes in gastrointestinal
hormones after sleeve gastrectomy and Roux-En-Y gastric
bypass surgery for morbidly obese type 2 diabetic subjects.
Surg Endosc 2012, 26:2231-2239.
52. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH:
Glucagon-like peptide-2 enhances intestinal epithelial barrier
function of both transcellular and paracellular pathways in the
mouse. Gut 2000, 47:112-119.
53. Billiauws L, Bataille J, Boehm V, Corcos O, Joly F: Teduglutide for
treatment of adult patients with short bowel syndrome. Expert
Opin Biol Ther 2017, 17:623-632.
54. Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C,
Chabenne J, Zhang L, Habegger KM, Fischer K et al.: A rationally
designed monomeric peptide triagonist corrects obesity and
diabetes in rodents. Nat Med 2015, 21:27-36.
This paper reported the development of a unimolecular triagonist of
glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. This new monomeric peptide
reduced body weight and diabetic complications in rodent models of
obesity. The direct comparison with bariatric surgery remain to be done.
55. Tscho¨p MH, Finan B, Clemmensen C, Gelfanov V, Perez-Tilve D,
Mu¨ller TD, DiMarchi RD: Unimolecular polypharmacy for
treatment of diabetes and obesity. Cell Metab 2016, 24:51-62.

www.sciencedirect.com